Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4351-4360 Newer>

The Motley Fool November 15, 2007 Brian Lawler	Flamel Now Part of Wacky Lawsuit Hijinks Multiple class action shareholder lawsuits targeting Flamel Technologies are announced, following a failed study of the company's lead drug.
The Motley Fool November 15, 2007 Rich Smith	Foolish Forecast: Mulling Medtronic In advance of earnings reports, analysts expect sales from the medical-equipment maker to remain flat and profit to fall slightly.
National Defense December 2007 Breanne Wagner	Computer Simulations of Stressful Environments Help Boost Performance Computer simulation" and "psychologist" are not terms usually used in the same sentence. But one company is trying to fuse the two via cognitive science.
The Motley Fool November 14, 2007 Jack Uldrich	The Week in Innovation Investors interested in the future of robotic medical technology, such as neurosurgical robots, carbon nanotubes, and printable organs, should keep an eye on these companies: Intuitive Surgical... IMRIS... Hansen Medical... Stereotaxis...
The Motley Fool November 14, 2007 Brian Lawler	Busy Times Ahead for Cardiome Keep an eye on Canadian drug developer Cardiome Pharma over the next three months; its entire pipeline of drugs will be receiving regulatory scrutiny during this time.
The Motley Fool November 14, 2007 Brian Lawler	Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note.
The Motley Fool November 14, 2007 Brian Lawler	Neurochem's Crazy Choice Neurochem chooses a risky path for its lead drug candidate, attempting to have its Alzheimer's disease medication marketed as a dietary supplement.
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool November 13, 2007 Brian Lawler	Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash.
<Older 4351-4360 Newer> Return to current articles.